Abstract:Background TNF-inhibitors could significantly improve disease activity of SpA patients, however, there is still no answer to the effect of prolonged the interval of TNF-inhibitors on MRI changes. Objectives The aim of the study was to investigate whether prolonged the interval of TNF-inhibitor injection could maintain SpA at low disease activity and improve imaging changes of sacroiliac joint. Methods A total of 98 SpA patients were included and 67 of them received TNF-i with or without conventional DMARDs. TNF-i included Etanercept, Infliximab and Adalimumab. The full dosage treatment was defined as patients received Etanercept 50 mg per week, Infliximab 4 mg/kg at 0, 2, 6 week and Adalimumab 40 mg every two weeks. The dose of Etanercept was gradually reduced to 50 mg every two weeks, 50 mg every three weeks and then 50 mg per month. The infusion of Infliximab was reduced to every 8 weeks, every 12 weeks and then every 16 weeks. The interval of Adalimumub injection was changed from 3 weeks to 4 weeks and then to two months. After full dose treatment in the first 3 months, patients who administrated TNF-i were evaluated every 3–6 months. According to laboratory tests including ESR, CRP and IgA levels, BASDAI, BASFI, ASDAS results and sacroiliac joint SPARCC scores, the interval of TNF-i treatment was prolonged gradually. Fat metaplasia, bone erosion, sclerosis and ankylosis changes on MRI were compared between baseline, 4–6 months and 1–2 years. Results After 3 months of treatment, inflammatory indexes, BASDI, BASFI, ASDAS and SPARCC scores were significantly lower than baseline (P<0.05). After 4–6 months of treatment, ESR, CRP and IgA levels were greatly lower than before (8 (3,25) vs. 2 (1,3) mm/h, 4.97 (1.83,14.5) vs. 1.71 (1.24,2.82) mg/l, 2.96±1.34 vs. 2.20±1.01mg/l, Table 1, P<0.01). Compared to baseline, significant reduction of BASDAI and BASFI score was observed in TNF-inhibitor group. The SPARCC scores in TNF-i group also decreased significantly (Figure1, P<0.01). There was no significant progress in fat metaplaisa, bone erosions, sclerosis and ankylosis during the follow-up period (P>0.05). Even though the inflammatory indexes and clinical evaluation of non-TNF-i group did not improved remarkably, SPARCC score were significantly reduced at 4–6 months and 1–2 years (P<0.05).Table 1. ESR, CRP and IgA changes before and after treatment Baseline 3 months 4–6 months 7–9 months 9–12 months 12–24 months ESR (mm/h) TNF-inhibitor 8 (3,25) 2 (1,3.75)** 2 (1,3)** 7 (2,9) 2.93 (2,6) 5.05 (2,17.75) non-TNF-inhibitor 10 (5,36) – 2 (2,8) – – 4 (0.5,10.5) CRP (mg/L) TNF-inhibitor 4.97 (1.83,14.5) 1.54 (1.03,3.02)* 1.71 (1.24,2.82)** 4.89 (1.95,8.75) 2.01 (1.25,4.37) 4.21 (1.0,10.83) non-TNF-inhibitor 6.85 (3.11,16.05) – 1.95 (1.59,5.34) – – 4.72 (1.8,7.43) IgA (mg/L) TNF-inhibitor 2.96±1.34 1.88±1.38 2.20±1.01** 1.92±1.63 1.78±1.32 2.45±1.63 non-TNF-inhibitor 3.47±1.63 – 1.95±1.35 – 1.79±2.53 1.47±1.48 *P<0.05, **P<0.01. Conclusions TNF-i could reduce clinical and imaging inflammatory degree. Prolonged the interval of TNF-i treatment could maintain low disease activity and improve bone marrow edema, whereas fat metaplasia, bone erosion, sclerosis and ankylosis were not exacerbated. Disclosure of Interest None declared

Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study

Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies

Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE

[A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Study of Etanercept in Treatment of Ankylosing Spondylitis].

Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

Etanercept/celecoxib on Improving MRI Inflammation of Active Ankylosing Spondylitis: A Multicenter, Open-Label, Randomized Clinical Trial.

Erosions on T1-weighted MRI vs Radiography of Sacroiliac Joints in Recent-onset Axial SpA: 2-year Data (EMBARK Trial and DESIR Cohort)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis

Clinical Efficacy of Etanercept for Treating Ankylosing Spondylitis in 60 Cases

Etanercept as Monotherapy in Patients with Psoriasis

A short-term study on half-value dose and decrement etanercept plus conventional therapy in active ankylosing spondylitis

THU0399 Tapering Therapy of Tnf-Inhibitor for Mri Changes in Spondyloarthritis

Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

"Long-term MRI findings in Ankylosing spondylitis patients treated with TNF inhibitors for a decade"

Clinical and structural damage outcomes in axial spondyloarthritis patients receiving NSAIDs or advanced therapies: a description of a real-life cohort

Long-Term Real-Life Data from Five Italian Referral Centers

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study